Alectinib showed a 22% reduction in death risk compared to crizotinib in advanced ALK-positive NSCLC, with a median OS of 81.1 months versus 54.2 months. Significant OS benefits were observed in ...
Omeros Corporation maintained with Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for ...
Halloween today is about candy, costumes, and spooky fun, with children dressed as superheroes and princesses going ...
The Nashville Zoo’s okapi ambassador helps raise awareness for conservation and World Okapi Day. Learn more about this ...
Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback